On Feb. 28, 2020, Altimmune announced the advancement of a novel single-dose, intranasal vaccine using Altimmune’s proprietary technology to protect against COVID-19, the disease caused by the SARS-CoV-2 virus.

Altimmune had completed the design and synthesis of the vaccine and was advancing it toward animal testing and manufacturing.